Wells Fargo upgraded Doximity (DOCS) to Equal Weight from Underweight with a price target of $62, up from $55. The firm is also raising estimates on product-led growth tailwinds, drug pipeline, and checks pointing to healthy pharma commercial activity. This should translate into positive near-term momentum on earnings, but valuation keeps Wells on the sidelines.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DOCS:
- Doximity’s Hold Rating: Navigating Market Momentum and Macroeconomic Uncertainties
- Doximity’s Mixed Market Signals: Positive Growth Amidst Budget Concerns and Rising Competition
- Doximity’s Hold Rating: Balancing Positive Momentum with Legislative Risks and Market Dynamics
- Doximity price target raised to $61 from $52 at Truist
- Doximity upgraded to Outperform from In Line at Evercore ISI